Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
ATHE Stock | USD 3.34 0.38 10.22% |
About 61% of Alterity Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Alterity Therapeutics suggests that many traders are alarmed. The current market sentiment, together with Alterity Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Alterity Therapeutics stock news signals to limit their universe of possible portfolio assets.
Alterity |
MELBOURNE, Australia and SAN FRANCISCO, Nov. 19, 2024 -- Alterity Therapeutics , has a
Read at gurufocus.com
Alterity Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Alterity Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Alterity Therapeutics Fundamental Analysis
We analyze Alterity Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Alterity Therapeutics is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Alterity Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Alterity Therapeutics stock to make a market-neutral strategy. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics with similar companies.
Peers
Alterity Therapeutics Related Equities
ARTL | Artelo Biosciences | 1.74 | ||||
ANEB | Anebulo Pharmaceuticals | 0.61 | ||||
SRZN | Surrozen | 1.08 | ||||
TARA | Protara Therapeutics | 1.17 | ||||
PMVP | Pmv Pharmaceuticals | 1.95 | ||||
HCWB | HCW Biologics | 2.44 | ||||
MNPR | Monopar Therapeutics | 2.78 | ||||
NBY | NovaBay Pharmaceuticals | 3.03 | ||||
ANTX | AN2 Therapeutics | 3.70 | ||||
ATXI | Avenue Therapeutics | 4.62 | ||||
ADIL | Adial Pharmaceuticals | 4.67 | ||||
RNAZ | Transcode Therapeutics | 4.99 | ||||
QNRX | Quoin Pharmaceuticals | 6.06 | ||||
RVPH | Reviva Pharmaceuticals | 6.50 | ||||
ADTX | Aditxt | 10.53 |
Complementary Tools for Alterity Stock analysis
When running Alterity Therapeutics' price analysis, check to measure Alterity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alterity Therapeutics is operating at the current time. Most of Alterity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alterity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alterity Therapeutics' price. Additionally, you may evaluate how the addition of Alterity Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |